Cost effectiveness of Becaplermin in the treatment of diabetic foot ulcers in four European countries.
- 1 January 2001
- journal article
- research article
- Published by Springer Nature in PharmacoEconomics
- Vol. 19 (7) , 767-778
- https://doi.org/10.2165/00019053-200119070-00005
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- The Cost-effectiveness of Treating Diabetic Lower Extremity Ulcers with Becaplermin (Regranex): A Core Model with an Application Using Swedish Cost DataValue in Health, 2000
- Efficacy and safety of becaplermin (recombinant human platelet‐derived growth factor‐BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studiesWound Repair and Regeneration, 1999
- Consensus Development Conference on Diabetic Foot Wound Care: 7-8 April 1999, Boston, Massachusetts. American Diabetes Association.Diabetes Care, 1999
- The burden of diabetic foot ulcersThe American Journal of Surgery, 1998
- Long-Term Costs for Foot Ulcers in Diabetic Patients in a Multidisciplinary SettingFoot & Ankle International, 1995
- Topical Treatment of Diabetic Foot Ulcers: an Economic Analysis of Treatment Alternatives and StrategiesDiabetic Medicine, 1995
- Diabetes mellitus. Prevention of amputationJournal of the American Podiatric Medical Association, 1994
- Diabetic foot ulcers in a multidisciplinary setting An economic analysis of primary healing and healing with amputationJournal of Internal Medicine, 1994
- Definitions and Guidelines for Assessment of Wounds and Evaluation of HealingArchives of Dermatology, 1994
- The Dysvascular Foot: A System for Diagnosis and TreatmentFoot & Ankle, 1981